NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alkermes plc ("Alkermes" or the "Company") (NASDAQ: ALKS). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/alks.

The investigation concerns whether Alkermes and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On November 6, 2017, U.S. Senator Kamala Harris revealed that she is opening an investigation into the Alkermes sales practices for its opioid-addiction treatment Vivitrol. Senator Harris said that the Company "aggressively marketed" its medication, convincing judges and prison officials to use it rather than more proven addiction treatments and spent hundreds of thousands of dollars lobbying policymakers. Following this news, Alkermes stock dropped $2.23, or 4.37%, to close at $48.76 on November 6, 2017.

If you are aware of any facts relating to this investigation, or purchased Alkermes shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/alks. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC